Submit Content
Get the latest delivered to your inbox
Privacy Policy

Now Reading

Seagen Publishes Inaugural Corporate Responsibility Report

- Report reflects Seagen’s Passion for Patients + Sustainable Innovation - Overview of ESG priorities, achievements, and future commitments -

Seagen Publishes Inaugural Corporate Responsibility Report

- Report reflects Seagen’s Passion for Patients + Sustainable Innovation - Overview of ESG priorities, achievements, and future commitments -

Published 12-07-21

Submitted by Seagen

BOTHELL, Wash., December 7, 2021 /CSRwire/ - As a demonstration of its long-term environmental, social, and governance (ESG) commitments, Seagen Inc. (Nasdaq:SGEN) today announced the release of its inaugural Corporate Responsibility Report. The report highlights Seagen’s dedication to patients, innovative science, transformative therapies, and how the company aims to operate in a sustainable manner. Available online at www.seagen.com, the report features employee insights, case studies, and the company’s accomplishments and future areas of focus.

“Seagen is a multi-product oncology company with operations in the United States, Canada and across Europe, enabling us to meet the needs of a wide range of people living with cancer,” said Clay Siegall, Ph.D., President, Chief Executive Officer, and Chairman of the Board at Seagen. “This report reflects our core values and dedication to our mission of developing innovative cancer therapies, while operating in a responsible manner as we continue to grow and expand our business.”

Seagen’s report Passion for Patients + Sustainable Innovation reflects the deep-rooted commitment and relentless drive to help patients around the world. Seagen’s Corporate Responsibility strategy and ESG disclosures are organized into four pillars: Innovation for a Sustainable Future, Patient & Community Care, Employee Empowerment, and Responsible Stewardship.

Key highlights detailed in the Corporate Responsibility report include:

  • Receiving FDA approval of three new oncology medicines in the past two years, empowering our ability to help a broader range of patients and expanding our commercial portfolio to four approved therapies
  • Advancing 17 programs for a range of solid tumors and hematologic malignancies, including our approved products and early- and late-stage pipeline
  • Appointing the first Head of Diversity, Equity, and Inclusion (DEI), forming an executive-level governance committee to oversee DEI strategy, goals, and execution, and creating four new employee resource networks
  • Supporting more than 60 patient organizations through partnerships, and financial funding through employee matching, advocacy grants and corporate sponsorships
  • Increasing headcount by approximately 30 percent for the third year in a row, reflecting Seagen’s success in attracting and retaining top talent
  • Striving to be responsible stewards of the environment and preparing to set a baseline year for emissions post-COVID-19 in order to effectively manage energy, waste, and water usage
  • Conducting an extensive prioritization analysis that yielded a focused list of ESG topics most relevant to Seagen and its key stakeholders

About Seagen

Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Seagen Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to Seagen’s commitments, expectations, goals, and aspirations regarding ESG, corporate responsibility, sustainability, environmental, employee, and business matters. Forward-looking statements are aspirational and based on Seagen management’s beliefs and assumptions and on information currently available to them. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Such statements may be based on standards for measuring progress that are still developing, internal controls and process that continue to evolve, and assumptions that are subject to change in the future. Forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

###

Media Contact
David Caouette
Vice President, Corporate Communications
(310) 430-3476
dcaouette@seagen.com

Investor Contact
Peggy Pinkston
Senior Vice President, Investor Relations
(425) 527-4160
ppinkston@seagen.com

Seagen Logo

Seagen

Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

More from Seagen

Join today and get the latest delivered to your inbox